

Remarks

A careful review of the Examiner's remarks as presented in the Final Action of June 14, 2004 and the Advisory Action of January 18, 2005 indicates that Claim 153 is allowable. By removing language pertaining to per cent sequence homology, and the like, it appears that all rejections whether presented under sections 102 or 112 have been made moot. Applicant respectfully requests that the application proceed to allowance on this basis. Applicant notes to the record that the present amendments do not indicate agreement with any rejection presented, and such amendments are made to facilitate immediate allowance of an important claim. Additional continuation/divisional applications will be filed directed to claims that have been amended or cancelled herewith, or which have been previously withdrawn from consideration.

Conclusion

A Petition for Extension of Time (5 months) including authorization to charge Applicants' Deposit Account No 16-1445 is attached. An early and favorable action is respectfully requested. The Examiner is requested to contact the undersigned to resolve any remaining issues.

Respectfully submitted,

Date:

7/13/05

E. Victor Donahue  
E. Victor Donahue  
Attorney for Applicant(s)  
Reg. No. 35,492

Pfizer, Inc  
Patent Department, 5th Floor  
150 East 42nd Street  
New York, NY 10017-5755  
(212) 733-2739